logo
Plus   Neg
Share
Email

NiSource Reaffirms FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the second quarter, electric utility NiSource Inc. (NI) on Wednesday reaffirmed its adjusted net operating earnings guidance for the full-year 2019.

For fiscal 2019, company continues to project adjusted net operating earnings in the range of $1.27 to $1.33 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.30 per share for the year. Analysts' estimates typically exclude special items.

Further, the company continues to make 2019 capital investments of $1.6 to $1.7 billion and grow its net operating earnings per share and dividend by 5 to 7 percent each year through 2022. It also expects to make capital investments of $1.6 to $2.0 billion annually from 2020 through 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Justice has reached a settlement agreement with a Texas-based Taco Bell franchise owner for immigration-related discrimination against certain employees. The settlement resolves the DOJ's investigation into whether MUY Brands LLC, and a related management company, MUY Consulting Inc., violated the Immigration and Nationality Act. Starbucks is gearing up for the upcoming holiday season by introducing its 2019 holiday flavors in U.S. grocery stores. The launch of the coffee giant's holiday line-up this year includes returning holiday favorites as well as a new item. Customers can now take home products that are making a comeback such as Starbucks Holiday Blend K-Cup and Ground Coffee, Peppermint Mocha Flavored Ground Coffee, Peekay International issued a recall of 7 ounce and 14 ounce packs containing Keshav Dry Apricot food treats as they contain undeclared allergens such as sulfites, according to a statement published by The U.S. Food and Drug Administration. Consumption of the product by those allergic or having severe sensitivity to sulfites could run the risk of serious or life-threatening allergic reactions.
Follow RTT
>